Lexicon Pharmaceuticals, Inc.’s (NASDAQ:LXRX) telotristat etiprate, the first oral therapy in development for the treatment of carcinoid syndrome (CS), was associated with patient-reported improvements in social and physical function and emotional well-being according to new exit interview data from the Phase 3 TELESTAR study presented at the 2015 Neuroendocrine Tumor Society Annual Symposium in Austin, Texas.
Telotristat etiprate, Lexicon’s most advanced product candidate, met the TELESTAR study’s primary endpoint with clinically meaningful reductions in bowel movement frequency in cancer patients whose carcinoid syndrome was not adequately controlled by somatostatin analog (SSA) therapy. New data released from interviews with participating patients who completed the randomized treatment portion of the TELESTAR study demonstrated that these reductions were meaningful to those patients and led to improvements in social and physical function and emotional well-being.
“Many patients with metastatic neuroendocrine tumors are now able to live longer lives. Unfortunately, uncontrolled carcinoid syndrome often makes daily life difficult for those patients,” said Pablo Lapuerta, M.D., Lexicon Executive Vice President and Chief Medical Officer. “We are pleased that these patient-reported experiences suggest that telotristat etiprate may offer a meaningful benefit to the quality of life of those patients.”
Carcinoid syndrome is a rare disease affecting thousands of cancer patients with metastatic neuroendocrine tumors that have spread to the liver and other organs from the gastrointestinal tract. The condition is characterized by frequent and debilitating diarrhea, facial flushing, abdominal pain, fatigue and other serious consequences that prevent patients from leading active, predictable lives. (Original Source)
Shares of Lexicon Pharmaceuticals closed last Friday at $11.08. LXRX has a 1-year high of $15.79 and a 1-year low of $5.60. The stock’s 50-day moving average is $12.17 and its 200-day moving average is $9.37.
On the ratings front, Lexicon Pharmaceuticals has been the subject of a number of recent research reports. In a report issued on September 28, Wedbush analyst Liana Moussatos reiterated a Buy rating on LXRX, with a price target of $19, which represents a potential upside of 71.5% from where the stock is currently trading. Separately, on August 10, J.P. Morgan’s Jessica Fye downgraded the stock to Hold and has a price target of $14.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Liana Moussatos and Jessica Fye have a total average return of 13.4% and -25.8% respectively. Moussatos has a success rate of 37.4% and is ranked #229 out of 3788 analysts, while Fye has a success rate of 0.0% and is ranked #3642.
Lexicon Pharmaceuticals Inc operates as a biopharmaceutical company engaged in discovery and development of breakthrough treatments for human disease.